Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 10/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2166623 | 1.00 | LMNA (0.48) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL29151786 | 0.98 | SMN1; SMN2 (0.46) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL7508589 | 0.91 | LMNA (0.62) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL3346971 | 0.87 | TSHR (0.50) | ALDH1A1TSHRFDPSSMPD1GGPS1 | |
| SCHEMBL1639544 | 0.87 | TSHR (0.50) | ALDH1A1TSHRFDPSSMPD1GGPS1 | |
| Trifluoroacetic Acid SCHEMBL7991180 | 0.85 | CES2 (0.49) | HSD17B10MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL5382441 | 0.85 | CES2 (0.49) | HSD17B10MEN1KMT2A | |
| SCHEMBL27778757 | 0.85 | TSHR (0.47) | ALDH1A1TSHRFDPSSMPD1GGPS1 | |
| SCHEMBL398718 | 0.83 | TSHR (0.43) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL5862701 | 0.83 | TSHR (0.43) | LMNAALDH1A1TSHRHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759564-B2 | Amidoacetonitrile compounds having pesticidal activity | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2301931-B1 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-20120232138-A1 | AMIDOACETONITRILE COMPOUNDS HAVING PESTICIDAL ACTIVITY | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| EP-2301931-A1 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| CN-101410389-A | Organic compounds | NOVARTIS AG (CH) | 2009-04-15 | — | — | CN | disclosed |
| EP-2001866-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| EP-0948483-B1 | FARNESYL TRANSFERASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2002-03-13 | — | — | EP | disclosed |
| EP-1042329-A1 | NOVEL FARNESYL TRANSFERASE INHIBITORS, PREPARATION, PHARMACEUTICAL, COMPOSITIONS CONTAINING THEM AND USE FOR PREPARING MEDICINES | Aventis Pharma S.A. (FR) | 2000-10-11 | — | — | EP | disclosed |
| CN-1242000-A | Farnesyl transferase inhibitors | RHONE POULENC RORER SA (FR) | 2000-01-19 | — | — | CN | disclosed |
| EP-0948483-A1 | FARNESYL TRANSFERASE INHIBITORS | Aventis Pharma S.A. (FR) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999033834-A1 | NOVEL FARNESYL TRANSFERASE INHIBITORS, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE FOR PREPARING MEDICINES | AVENTIS PHARMA S.A. (FR) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998029390-A1 | FARNESYL TRANSFERASE INHIBITORS | RHONE-POULENC RORER S.A. (FR) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232138-A1 | AMIDOACETONITRILE COMPOUNDS HAVING PESTICIDAL ACTIVITY | ACHE, NAAA, NIT2 | LMNA 936/4885ALDH1A1 2992/4885TSHR 2329/4885 |
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | LMNA 1104/4885ALDH1A1 215/4885TSHR 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.